CDKN1B 抗体
Quick Overview for CDKN1B 抗体 (ABIN7113177)
抗原
See all CDKN1B 抗体适用
宿主
克隆类型
标记
应用范围
-
-
纯化方法
- Immunogen affinity purified
-
纯度
- ≥95 % as determined by SDS-PAGE
-
免疫原
- cyclin-dependent kinase inhibitor 1B(p27, Kip1)
-
亚型
- IgG
-
-
-
-
应用备注
- WB: 1:200-1:2000, IP: 1:200-1:1000, IHC: 1:50-1:500, IF: 1:50-1:500
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
储存条件
- -20 °C
-
储存方法
- -20°C for 12 months (Avoid repeated freeze / thaw cycles.)
-
有效期
- 12 months
-
-
- CDKN1B (Cyclin-Dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B))
-
别名
- P27, KIP1
-
背景
- Synonyms:CDKN1B, CDKN4, KIP1, MEN1B, MEN4, P27, P27, KIP1, P27KIP1 Background:CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.
-
分子量
- 27 kDa
-
基因ID
- 1027
-
UniProt
- P46527
-
途径
- Cell Division Cycle, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Peptide Hormone Secretion, Negative Regulation of Hormone Secretion, Sensory Perception of Sound, Mitotic G1-G1/S Phases, DNA Replication, Positive Regulation of Endopeptidase Activity, Synthesis of DNA, Autophagy
抗原
-